On Thursday, Exscientia plc (NASDAQ:EXAI) agreed to merge with Recursion Pharmaceuticals Inc. (NASDAQ:RXRX). Exscientia shareholders will receive 0.7729 Recursion shares for each Exscientia share, ...

PHILADELPHIA, April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage ...

On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...

Recursion shares jumped over 18% after launching Boltz-2, a breakthrough AI model with MIT that predicts molecular binding The open-source model significantly accelerates drug discovery, making ...

Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but at ...

One person that helped bring the chill was an analyst cutting his price target. Another two were executives at the biotech selling chunks of stock. 10 stocks we like better than Recursion ...